Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Emerging ibrutinib-based combinations in CLL

Jennifer Woyach • 8 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Antibodies Ibrutinib Obinutuzumab Venetoclax
CAPTIVATE GLOW

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, comments on promising ibrutinib-based combinations under development for the treatment of chronic lymphocytic leukemia (CLL), including doublet therapies such as venetoclax-ibrutinib, or triplet combinations such as ibrutinib-venetoclax-obinutuzumab, and more novel strategies combining ibrutinib with bispecific antibodies. In the future, ibrutinib may be combined with newer BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jennifer Woyach

1:04
6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL
Jennifer Woyach • 8 Dec 2023
1:18
Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUIN
Jennifer Woyach • 8 Dec 2023
2:57
LP-168: a novel next-generation BTK inhibitor with dual activity in CLL
Jennifer Woyach • 8 Dec 2023
0:49
BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL
Jennifer Woyach • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals